• Thus far clinical data indicate that IDO

  2024-04-17

  

  Thus far, clinical data indicate that IDO1 inhibitors have manageable toxicity, albeit with a relatively short period of treatment in a small number of patients. KYN is a pluripotent mediator and key intermediate for the synthesis of a host of downstream KP metabolites that are implicated in inflamm

• There are human genes in the SLC

  2024-04-17

  

  There are 12 human genes in the SLC5A family, and 6 of these are expressed in human heart (Table 2). Little is known about SGLT proteins in the heart. Zhou et al. [56] reported the presence of SGLT1 mRNA in the human heart. Researchers have found that levels of SGLT1 mRNA in heart are approximately

• br Introduction Clinical manifestations of Alzheimer s disea

  2024-04-17

  

  Introduction Clinical manifestations of Alzheimer's disease (AD) are mainly characterized by progressive intellectual deterioration, memory impairment, cognitive impairment, and psychiatric symptoms. The pathogenesis of AD remains unclear, mainly containing genetic factors, neurotransmitter disor

• br Therapeutic advantages and clinical implications of caffe

  2024-04-17

  

  Therapeutic advantages and clinical implications of caffeine treatment in ROP The demonstration of the role of the adenosine receptor in development of ROP and protection by caffeine suggests two potential therapeutic strategies with high translational potential: a) modification of caffeine treat

• For the NSCLC patients with EGFR

  2024-04-16

  

  For the NSCLC patients with EGFR-activating mutations, EGFR-TKIs (gefitinib and erlotinib) are effective clinical therapies [21], [22]. However, approximately 10% of patients harboring EGFR-sensitizing mutations exhibit intrinsic resistance, and up to 40% do not attain a major response to treatment

• Recent studies demonstrated FoxO a

  2024-04-16

  

  Recent studies demonstrated FoxO3a enhances the protective functions of autophagy in response to environmental stress , . FoxO3a coordinately activates autophagy by binding directly to the promoters of autophagy-related genes, including LC3, Gabarapl1, Beclin1, and Atg12 in atrophied skeletal muscle

• Fig summarizes the oxidative metabolism

  2024-04-16

  

  Fig. 1 summarizes the oxidative metabolism of arachidonic sq 22 by lipoxygenases cyclooxygenases and cytochrome P450. Lipoxygenases in humans are expressed in a tissue-specific fashion: 5-LOX is mainly expressed in leukocytes, 12-LOX in platelets, and 15-LOX-1 in reticulocytes, eosinophils, and ma

• Non steroidal anti inflammatory drugs which include

  2024-04-16

  

  Non-steroidal anti-inflammatory drugs, which include aspirin and ibuprofen, target COX-2 activity to inhibit inflammation. It has been shown that daily use of a nonsteroidal anti-inflammatory drugs is associated with reduced ER-positive breast cancer recurrence in obese and overweight women. More pr

• Calpain Inhibitor XII We demonstrated clearly that the

  2024-04-16

  

  We demonstrated clearly that the overexpression of sFlt-1 significantly increased arginase Calpain Inhibitor XII and enhanced arginase activity in HUVECs (Fig. 3). NO formation is related inversely to serum levels of sFlt-1 in preeclampsia [11]. The disorder of NO formation, which was involved in hy

• In large biopsies series from ALK NSCLC treated patients the

  2024-04-16

  

  In large biopsies series from ALK+ NSCLC treated patients, the number of detected mutations increased after second generation ALKi (Gainor et al., 2016) and in one study were present in 56% of the entire cohort (Shaw et al., 2013b). For example, the rate of G1202R mutations increases from 2% in post

• Amyloid β-Peptide (1-42) br AHR mediates TCDD toxicity and w

  2024-04-16

  

  AHR mediates TCDD toxicity and wasting syndrome TCDD causes numerous toxicities in laboratory animals, including teratogenesis, hepatic steatosis, thymic atrophy, immune dysfunction and a lethal wasting syndrome [17]. The dose-dependent sensitivity to TCDD-induced toxicities varies widely among l

• The A b action occurs in conditions

  2024-04-15

  

  The A2b action occurs in conditions where high concentrations of adenosine is generated, so its blockage does not interfere with other physiological processes mediated by adenosine and others AR [105]. Furthermore the A3 receptor was shown to have pro-apoptotic effects on tumor lines of breast, lung

• In the late s Solvay Pharmaceuticals discontinued the Phase

  2024-04-15

  

  In the late ‘90s, Solvay Pharmaceuticals discontinued the Phase 2 development of a promising potent and highly selective A1AR antagonist based on the pyrrolopyrimidine scaffold, SLV320 [43] (2, Chart 1, also named derenofylline; Ki hA1AR = 1 nM), for the treatment of acute heart failure [24]. In the

• Although the effects of adenosine receptor signaling

  2024-04-15

  

  Although the effects of adenosine receptor signaling in acute renal IRI have been attributed to the generation of high concentrations of adenosine, we have recently reported an increase in kidney levels of both AMP and adenosine, with a concomitant fall in ATP and ADP. We have also previously demons

• The physiological effect of adenosine

  2024-04-15

  

  The physiological effect of adenosine is now considered a new direction in halting the progression of organ damage in cardiovascular disease [24], [25], [26]. Adenosine has diverse functions, depending on its interaction with different receptor subtypes: A1, A2A, A2B, and A3[24], [25], [26]. Stimula

15236 records 140/1016 page Previous Next First page 上5页 136137138139140 下5页 Last page